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• GECPAR is an enhancer RNA transcribed from the super-enhancer of the POU2AF1 gene in normal 
and neoplastic germinal center B cells 
• GECPAR has a tumor suppressor activity in DLBCL and is involved in cell proliferation and 
differentiation  







Enhancers are regulatory regions of DNA, which play a key role in cell-type specific differentiation and 
development. Most active enhancers are transcribed into enhancer RNAs (eRNAs) that can regulate 
transcription of target genes by means of in cis as well as in trans action. eRNAs stabilize contacts between 
distal genomic regions and mediate the interaction of DNA with master transcription factors. Here, we 
characterised an enhancer RNA, GECPAR (GErminal Center Proliferative Adapter RNA), that is specifically 
transcribed in normal and neoplastic germinal center B-cells from the super-enhancer of POU2AF1, a key 
regulatory gene of the germinal center reaction. Using diffuse large B cell lymphoma cell line models, we 
demonstrated the tumor suppressor activity of GECPAR, which is mediated via its transcriptional regulation 




Enhancers are regulatory DNA regions that positively drive gene transcription across neighbouring genomic 
regions spanning many megabases and are characterised by distinct epigenetic features (1, 2): a high ratio 
of H3K4me1 to H3K4me3; enrichment of H3K27ac, which is deposited by the CREBBP/p300 complex (3); 
high accessibility to chromatin readers such as bromodomain and extraterminal domain (BET) proteins and 
transcription factors (TFs). Some enhancers are actively transcribed giving rise to noncoding RNAs called 
enhancer RNAs (eRNAs) (4). Transcribed enhancers are more acetylated, more enriched of TFs and 
coactivators, and are also more active in the transactivation of promoters, with which they interact inside 3D 
structures called enhancer-promoter loops (5). Clusters of enhancers, called super-enhancers (SEs), are 
strongly transcribed and produce several eRNAs controlling key genes, which regulate cellular development 
and differentiation (6, 7). eRNAs are crucial components of the regulatory chromatin machinery that controls 
the expression of key context-specific, protein-coding genes. They usually stabilize multiprotein complexes 
and constitute a scaffold for DNA loops by enforcing interactions between distant DNA regions, including 
those located on different chromosomes (8-11). As they lack a poly A tail, their activity is restrained to the 
site of transcription and they undergo rapid decay. However, polyadenylated long intergenic noncoding 
RNAs (lincRNAs) also comprise enhancer-derived noncoding transcripts (e-lncRNA) (12), and the 
stabilization of these eRNAs confers them the capability to act in trans, regulating several distant targets 
(13). 
Individual eRNAs are expressed in a tissue-specific manner. In normal B cells at various stages of 
differentiation, the expression of noncoding RNAs can more precisely define cellular subsets than protein-
coding transcripts (14, 15). In particular, eRNAs are differentially expressed during B cell development and 
they are associated with protein-coding genes that play an essential role in B cell differentiation.  
Diffuse large B cell lymphoma (DLBCL) derives from germinal center (GC) B cells. DLBCL is typically divided 
into two main subtypes: GC B cell-like (GCB DLBCL), whose transcriptional profile resembles that of light 
zone GC B cells, and activated B cell-like (ABC DLBCL), whose transcriptome resembles that of 
plasmablasts (16). However, DLBCLs within each of these subgroups exhibit biological, genetic and 
transcriptional heterogeneity (17-19). Lineage-specific and growth-dependent transcription factors like BCL6, 
Myc, NF-κB, p53, and E2F1 can activate specific genetic signatures, depending on the activation of unique 
subsets of enhancers (20, 21), and contribute to disease heterogeneity. Here, we studied a unique eRNA 
associated with the POU2AF1 gene, that we termed GECPAR, for GErminal Center Proliferative Adapter 
RNA. POU2AF1 encodes the protein OCA-B, coactivator of OCT2, a B cell specific transcription factor which 
plays a pivotal role in the regulation of normal and neoplastic GC B cells (22, 23). The SE proximal to 
POU2AF1 is the most activated SE in GCB DLBCL(23). Loss of GECPAR correlated with reduced 
transcription of TLE4, which is a negative regulator of LEF1, a Wnt pathway effector protein that in turn 
regulates also NF-κB. GECPAR loss also increased MYC expression and proliferation of DLBCL cell lines. 
Conversely, its overexpression impaired cell proliferation. Collectively, our data provides evidence of the 








Detailed descriptions of experimental methods are included in the Supplementary data. 
Human samples, cell lines, small interfering RNA transfection 
Established human DLBCL cell lines and Patient Derived Tumor Xenograft Cell lines (PDTX-CL) were grown 
as previously described (24). All patients providing samples gave written informed consent. Molecular and 
clinical data acquisition and PDTX establishment were approved and carried out in accordance with 
Declaration of Helsinki and were approved by Institutional Review Boards of the New York Presbyterian 
Hospital, Weill Cornell Medicine (WCM), New York, NY, and Ospedale San Giovanni Battista delle Molinette, 
Turin, Italy. Cell lines were checked for their identity (24). Cells were transfected with siRNAs or LNA using 
the 4D Nucleofector.  
GECPAR cloning and infection into lymphoma cells, RNA-Seq 
Cellular lysates were fractionated as previously described (25). For strand-specific qRT-PCR, only the 
forward primer was used to amplify the antisense strand and only the reverse primer to amplify the sense 
strand. 5’ and 3’ Rapid Amplification of cDNA Ends (RACE) was done using Invitrogen RACE System kits. 
GECPAR was cloned into the pGEM-T vector and subcloned in pCDH-CMV-MCS-EF1-copGFP. pCDH 
empty backbone or pCDH_GECPAR were transfected in HEK293T, and viral supernatant was then used to 
infect lymphoma cells. RNA-Seq in cell lines was performed using the NEBNext Ultra II Directional RNA 
Library Prep. 
CHART-seq 
CHART enrichment and RNAseH mapping experiments were performed following previously reported 
protocols (26, 27). The enrichment of CHART signals was determined relative to the oligo controls. 
Conservative enrichment profiles were determined using the SPP package (28) and MACS (29), as 





The super-enhancer associated with the POU2AF1 gene locus is transcribed in normal B cells and 
DLBCL cell lines 
Analysis of publicly available RNA-Seq data on RNA polyA+ or poly A- (31) showed that CD20+ cells 
express a non-polyadenylated portion of the LOC100132078 transcript and also two isoforms of a more 
abundant antisense transcript (Figure 1a, Figure S1a) . Due to its proximity to the POU2AF1 gene and its 
localization in a genomic region with characteristic SE features (highly acetylated, enriched in H3K4me1 but 
not H3K4me3, based on ENCODE ChIP-Seq data), we hypothesized that it could be an eRNA with particular 
relevance for GC B cells  
To confirm the eRNA length reconstructed in CD20+ cells, we performed 5’ and 3’ RACE in the DLBCL cell 
line OCI-LY1. For the 3’-end detection we ran two reactions, with or without the addition of an artificial polyA 
tail. We identified a transcript lacking a polyA tail and another that was 400 bases longer and naturally 
polyadenylated. Similarly to the forementioned poly A- transcript reported in CD20+ normal B cells, neither of 
the transcripts identified in DLBCL cells extended beyond the annotated first exon. The 5’ RACE reaction 
reverse transcribed from exon 4 did not identify a specific 5’-end for exon 1, indicating that the long 
annotated transcript, LOC100132078, was likely not stable in our model. Conversely, reverse transcribing 
from exon 1, we identified a 5’-end located at nucleotide +366, mirroring our in silico observations for CD20+ 
normal B cells (Figure 1a-b). We renamed the stabilized portion of LOC100132078 we had sequenced in the 
OCI-LY1 model as “GECPAR”. 
 
GECPAR is mainly chromatin associated and partially polyadenylated 
To further characterize the physical characteristics of GECPAR, RNA was extracted from cytoplasm, 
nucleoplasm and chromatin fractions. In GCB-DLBCL (OCI-LY1 and Karpas422) and ABC-DLBCL (HBL1, 
U2932) cell lines, GECPAR was transcribed but mostly retained on chromatin, in accordance with reported 
features of eRNA (6, 7). It was also clearly detected in the nucleoplasm and cytoplasm of OCI-LY1, a cell line 
with five-fold higher levels of chromatin-associated GECPAR than the other cell lines (Figure 
1c).Semiquantitative directional RT-PCR showed that chromatin association was particular to GECPAR 
since its antisense transcript, when expressed, was more ubiquitously distributed (Figure S1b). 
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Quantification of KCNQ1OT1, MALAT1 and beta-actin mRNAs served as a control for chromatin-associated, 
nuclear and cytosolic RNA, respectively (Figure S1c). 
Strong association of a transcript to chromatin usually correlates with its lack of polyadenylation consequent 
rapid degradation by the RNA exosome (32). To determine if these features were applicable to GECPAR, we 
assessed its polyadenylation status. The latter was abundant in total transcripts reverse-transcribed using 
random hexamers, especially in the two GCB-DLBCL cell lines. Conversely, when oligo-dT was used for 
reverse transcription, GECPAR was clearly detectable in only OCI-LY1, in agreement with the higher 
abundance of GECPAR in this cell line. (Figure 1d). 
 
GECPAR is predominantly transcribed in GCB DLBCL cell lines and patients 
We measured GECPAR transcription by directional qRT-PCR in 22 DLBCL cell lines (GCB, n.= 16; ABC, 
n.=8). The overlapping antisense transcript was evaluated in parallel as a control. GECPAR was more 
frequently expressed in GCB- than ABC-DLBCL cell lines (11/16 vs 0/8; P 0.001). In particular, it was 
expressed at high levels in five (OCI-LY1, OCI-LY1b, OCI-LY8, OCI-LY18, VAL), and at lower levels in six 
(SU-DHL-4, SU-DHL-6, SU-DHL-16, SU-DHL-8, SU-DHL-10, TOLEDO) GCB DLBCL cell lines. The 
transcript was barely detectable in the remaining five GCB and in all the eight ABC DLBCL cell lines, while 
the antisense transcript was more broadly expressed in all cell lines (Figure 2a). 
We also evaluated GECPAR level in a total RNA-Seq dataset (33) obtained from specimens derived from 
normal tonsil (n.=31) and DLBCL patients (GCB, n.=16; ABC, n.18). The transcript was significantly more 
expressed in normal cells compared to tumor cells, and, in accordance with our cell lines data, it was 
generally more abundant in GCB than in ABC DLBCL (Figure 2b). The higher GECPAR expression in GCB-
DLBCL was confirmed in a validation cohort of 74 patients (GCB, n.=31; non-GCB, n.=43) (GSE145043) 
(Figure S2a) and in a second one of 350 patients (GCB, n.=183; ABC, n.167) (GSE10846). Variation of 
GECPAR expression in DLBCL cell lines and patients might be partially explained by its unstable genomic 
locus (34-36). A focal deletion of the chromosomal region containing the eRNA was observed in 3/737 
mature lymphoid tumors (37-41) (Figure S2b).  
The normal tonsil derived cells were then subdivided according to B cell maturation stage (42). GECPAR 
was most highly expressed by centroblasts while naïve B cells expressed the lowest levels. This observation 
further underlined the specific transcription of GECPAR in GC derived cells. We also analysed a catalogue of 
murine lncRNA expressed in different developmental stages of B cell maturation (43). Similar to our 
observations in humans, the murine GECPAR orthologue was mainly expressed in GC B cells, confirming 
the specific and conserved association of GECPAR with the GC B cell transcriptional program (Figure S2c). 
 
GECPAR expression correlates with cell cycle genes and the GCB DLBCL oncogenic signature 
To identify a gene expression signature associated with GECPAR, we focused on the 16 GCB DLBCL cell 
lines with available expression profiling data (44) and split them in two groups based on the median 
GECPAR expression. We identified 122 significantly upregulated and 73 downregulated genes (abs log2 fold 
change ≥ 0.59 and P ≤ 0.05), that could divide GCB DLBCL cell lines into high and low GECPAR expressers 
(Figure 2c, Table S1). Transcripts that were more expressed in GECPAR high than in GEPCAR low 
expressers showed a significant enrichment of cell cycle genes and essential cell survival genes, while 
genes involved in MAPK and PI3K pathways, as well as LEF1 targets were comparatively less enriched 
(Figure 2d). 
When we divided the 16 GCB-DLBCL patient specimens according to GECPAR expression GECPAR-high 
specimens showed an enrichment of cell cycle genes, particularly the G2M checkpoint as well as genes 
essential for cell survival (Figure 2e, Table S2). Conversely, LEF1 targets and genes downstream of TGF-β 
and ATF2 were downregulated in DLBCLs with high GECPAR expression (Figure 2f). Comparison of the 
genes associated with differential GECPAR expression in cell lines and clinical specimens (Table S3, Figure 
S2d-e) revealed that common genes were mainly involved in negative regulation of the cell cycle Due to 
these observations, we hypothesized that GECPAR had an antiproliferative function. 
 
GECPAR exhibits anti-proliferative activity in DLBCL cells 
To investigate the putative antiproliferative role of GECPAR we induced degradation of GECPAR using LNA 
oligonucleotides in VAL, OCI-LY18 and OCI-LY1, three GCB DLBCL cell lines with high level of GECPAR 
and U2932, an ABC DLBCL with moderate GECPAR expression (Figure S3a). After 24 hours we measured 
POU2AF1 mRNA and observed a negligible effect on its expression (Figure S3b).Therefore, despite 
GECPAR transcription being dependent on activation of the same super-enhancer (Figure S3c-d) needed for 
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POU2AF1 transcription (Figure S3e), GECPAR itself was not essential for POU2AF1 transcription. 
Degradation of GECPAR led to an increase in cell proliferation in all the tested cell lines, suggesting a tumor 
suppressor function of GECPAR (Figures 3a, S3f-g). To further confirm the antiproliferative activity of 
GECPAR, we then overexpressed GECPAR in SUDHL2 and OCI-Ly10, two ABC cell lines with low 
GECPAR levels. The growth of stable GFP positive GECPAR-expressing cells (Fig. S3 h, i) was followed by 
imaging in real time for 5 days. In both cell models, we measured a significant reduction in proliferation of 
cells overexpressing GECPAR compared to control infected cells (Figure 3b,S3j). In particular, OCI-Ly10 
expressed very intense GFP fluorescence (Fig. S3i) and could grow as monolayer on L-poly-ornithin coated 
surface allowing monitoring the growth of cells with specific green fluorescence intensity. On the contrary, 
SUDHL2 tended to form clusters, despite of the L-poly-ornithin coating, and the instrument could hardly 
discriminate fluorescence from single cells over time. In that case, we could measure the cell growth by 
phase contrast image analysis, more accurately. The number of total cells and of GFP expressing cells 
counted at time 0 are reported in Fig. S3k.   
As further confirmation, we analyzed GECPAR function also in two ABC (PDTX-KD and PDTX-RRR) and 
two GCB (PDTX-SS and PDTX-RN) DLBCL PDX models. We confirmed that GECPAR was higher in the two 
GCB than ABC cases (Figure 3e). Furthermore, we selected the PDX cells with the highest GECPAR 
expression (PDTX-RN) and we silenced GECPAR by LNA antisense oligonucleotides (Figure S4a). 
GECPAR silencing increased the proliferation rate also in this model (Figure 3f, S4b). In addition, we 
overexpressed GECPAR in PDTX-KD cells, which had a very low amount of the transcript.  We seeded the 
cells 24h alter transduction and we followed them (Figure S4c). As for SUDHL2, although we could not 
monitor their growth along the whole experiment due to their tendency to form clusters, we measured GFP 
expression by FACS (Figure S4d), GECPAR expression by qRT-PCR (Figure S4e) and cell viability by MTT 
assay (Figure 3f) after nine days. As observed with ABC DLBCL cell lines, also PDX cells, derived from an 
ABC DBCL with low GECPAR expression, reduced their proliferation rate after GECPAR overexpression. 
 
GECPAR polarizes cells towards GCB transcriptional program 
We performed transcriptional analysis after GECPAR knockdown and overexpression in U2932 and 
SUDHL2 cells, respectively. Knockdown of GECPAR resulted in 1,099 significantly downregulated and 528 
upregulated genes (Table S4), while overexpression of GECPAR led to significant upregulation of 3,152 
genes and downregulation of 787 genes (Table S5). Genes upregulated after GECPAR silencing comprised 
proliferation genes, which were conversely downregulated in GECPAR-overexpressing cells. Further, while 
U2932, an ABC DLBCL with moderate basal GECPAR expression still presented an enrichment of 
oncogenic genes typical of ABC DLBCL after GECPAR knockdown (Figure 3d, Table S6, left), the other ABC 
DLBCL SUDHL2, showed an enrichment of GCB DLBCL genes (Figure 3e, Table S6, right), after GECPAR 
overexpression. Finally, GECPAR transcription was strongly induced by anti-IgM stimulation of the BCR 
(Figure S3l). Together, these observations provided further support of GECPAR’s role in maintaining the GC 
transcriptional program. 
 
GECPAR expression has favorable prognostic impact in GCB DLBCL patients 
We assessed the expression of GECPAR in 91 DLBCL patients treated with R-CHOP and its potential 
impact on the clinical outcome. We classified patients in three subgroups: low expressor (below the 15th 
percentile of the whole population), high expressor (over the 70th percentile), and neutral (in between). High 
expressor patients had a higher survival probability than low expressor (p value = 0.01) (Fig. 4a). Then, we 
looked at the high and low expressors based on their cell of origin. As expected by previous analysis (Fig 
S2a), the high expressors were mainly GCB patients. However, among GCB DLBCL patients, cases with low 
GECPAR expression had  the same risk of death as ABC patients, while the high expressors showed a 
better outcome (p value=0.03). All together, these observations further sustain the tumor suppressor role we 
attributed to GECPAR based on our in vitro experiments. 
 
GECPAR acts in trans regulating cell growth and differentiation by means of Wnt pathway 
To identify the genes directly regulated by GECPAR, we performed CHART-Seq in OCI-LY1 and U2932. We 
identified 4,172 peaks in OCI-LY1 and 692 peaks in U2932 (Figure 5a, Table S7-8). The most prominent 
peaks were validated in an independent CHART experiment by qRT, confirming the robustness of both the 
enrichment experiment and downstream analysis (Figure S5b). As an additional control, we measured the 
levels of transcripts associated with GECPAR binding including CREBBP, CREB5, TLE4 and CYLD. After 
24h of GECPAR silencing with LNA oligonucleotides in U2932, the levels of these transcripts were reduced 
by 50-80% (Figure S5c) and after 72h we noticed a reduction of 50% also in the level of CYLD and TLE4 
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proteins (Fig.S5d, top). We also measured the increase in protein levels in SUDHL2 and OCI-Ly10 stably 
overexpressing GECPAR, for TLE4 and CYLD, or CREBBP and CYLD, respectively (Fig.S5d, bottom). 
GECPAR capture was done with a set of probes, selected after RNAseH sensitivity assay (Figure S5a). Only 
peaks called by two different algorithms (MACS and SPP) were taken in account: 4,172 in OCI-LY1 and 692 
in U2932 (Figure 5a, Table S7-8). We identified a putative GECPAR binding motif. Among 78 CHARTseq 
peaks that fell within an interval of 10 kb in both cell lines there was a significant putative GECPAR binding 
motif (13 matches, p-values between 2.15 E-07 and 1.9 E-09) (Figure S5e), 
To identify biological processes directly influenced by GECPAR independently of the cell of origin, we 
analysed 325 genes bound by the eRNA in both OCI-LY1 and U2932. The most significantly enriched 
classes of genes belonged to the Wnt signaling pathway, cell growth and differentiation (Figure 5b). RNA-
Seq data after GECPAR knockdown showed modulation of three pathways associated with development, 
differentiation and proliferation and known to cross-talk with the Wnt pathway, such as TGF β, NF-κB and 
MAPK (Figure 5c) (45-47) .  Negative regulators of TGF-β pathways including SMAD7, SMURF1 and 
SMURF2 (Figure S6a) and negative regulators of MAPK signaling, DUSP1, DUSP8 and DUSP10 (Figure 
S6b), were downregulated, after GECPAR silencing. Some of the downregulated genes belonging to the 
aforementioned pathways are also negatively regulated by NF-κB (Figure S6c). Notably, WNT and MAPK 
pathways were also affected in SUDHL2 cells overexpressing GECPAR (Figure 5d).  
Intersection of CHARTseq and RNA-Seq data for U2932 cells with GECPAR knockdown identified MYC and 
PRDM1 among seven genes negatively regulated by GECPAR, indicating that the eRNA influenced both the 
proliferative capability, reducing MYC, and the terminal differentiation to plasma cells, reducing PRDM1, the 
genes coding for BLIMP1. Interestingly, 21 direct GECPAR upregulated targets were positively correlated 
with GECPAR expression also in GCB DLBCL specimens (Figure 54e). Among them there were KLF6, 
NOTCH2, components of BMP, cAMP and TNF-alpha pathways. Strikingly, we also identified TLE4 
(Groucho), which forms a corepressor complex with TCF/LEF1 and recruits HDACs to inhibit transactivation 
of TCF/LEF1 target genes (48). 
Our identification of GECPAR involvement in Wnt signaling prompted us to evaluate the activity of the 
tankyrase 1/2 (TNKS1/2) inhibitor, AZ6102, that prevents nuclear translocation of beta-catenin. (49). For the 
four ABC DLBCL cell lines we tested, GECPAR expression and sensitivity to AZ6102 were significantly anti-
correlated (Figure 6a), suggesting that expression of GECPAR sensitized cells to Wnt pathway inhibition. All 
seven GCB DLBCL cell lines tested where equally sensitive to Wnt pathway inhibition (Figure S7). The 
differential sensitivity to AZ6102 in ABC DLBCLs was not related to tankyrase expression, since protein 
levels were similar for the four cell lines (Figure 6a). Further, GECPAR overexpressing SUDHL2 cells were 
more sensitive to Wnt inhibition than the parental control, in terms of cell cycle perturbation. AZ6102 
treatment more readily caused G2/M arrest, subG1 accumulation and decreased re-entry in G1 in GECPAR 




eRNAs have recently started to be recognized as potent modulators of coding gene transcription (50, 51). 
Here, we provide the first evidence of a lncRNA, transcribed in a SE specifically active during maturation of 
GC B cells, which plays an antiproliferative role in DLBCL models and is associated with favorable clinical 
outcome in GCB DLBCL patients.  
The lncRNA LOC100132078 was previously annotated as an unknown ncRNA, mainly expressed in lymph 
nodes and testis (52), and reported among p53-induced eRNAs in breast cancer (53). Since it mapped 
inside a SE relevant for GC formation (3, 23, 43) and in a site of recurrent genomic instability in lymphoid 
tumors (34-36), we elucidated its role in DLBCL, the neoplastic counterpart derived from GC B cells. We 
defined this lncRNA as eRNA according to the main features of this class of ncRNA: it was encoded within a 
SE; it was a non-polyA chromatin-associated transcript: its expression, highly cell type specific, was 
dependent on enhancer activation. We also identified a stabilized 970 nucleotide-long transcript, which, 
based on its expression pattern, we named GECPAR. It was less expressed in DLBCL samples than in 
normal tonsil B cells and in vitro experiments showed an inverse correlation with cell proliferation, suggesting 
an antitumoral function. The latter was further supported by the association between high GECPAR 
expression and favorable outcome in GCB DLBCL patients. GECPAR did not seem to act by in cis 
transactivation of the juxtaposed POU2AF1 gene, which is strongly expressed in GC-derived malignancies 
(22). Indeed, although GECPAR and POU2AF1 transcript levels were correlated in cell lines and in clinical 
specimens, silencing of the eRNA did not strongly impair expression of the coding gene. This is not 
uncommon and might be due to redundant functions of multiple enhancers that target a given promoter (54). 
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On the contrary, GECPAR showed in trans activity and directly regulated the expression of several 
transcripts, mainly involved in cell growth and differentiation. These regulated genes were identified as 
common GECPAR targets in a GCB- and an ABC DLBCL cell line, both of which had constitutively high 
GECPAR expression.  
GECPAR expression was increased after BCR activation, an event that causes transcriptional reprograming 
of B cells. The exogenous overexpression of GECPAR in an ABC DLBCL cell line confirmed its ability to 
switch the lymphoma cell towards the GCB DLBCL transcriptional signature. 
Nuclear enriched lncRNA regulating transcription in trans have been described and they often modulate cell 
development (43, 55). We propose that GECPAR is used by normal GC B cells to fine-tune the balance 
between proliferation and differentiation by directly repressing MYC and PRDM1 expression. MYC has a 
stage-specific role in the GC, particularly in light zone B cells, namely centrocytes, from which GCB DLBCL 
tumor cells derive. After antigen-driven selection, B cells that still need to improve their antigen affinity can 
re-enter in the dark zone where they undergo additional cycles of somatic hypermutation. This so-called 
“cyclic re-entry” is critical for maintaining the GC and is induced by the re-expression of MYC via BCR 
activation through NF-κB and FOXO1 (56, 57). We propose GECPAR as a key surveillant of this process, as 
it directly represses MYC in that phase. Termination of the GC reaction is modulated by NF-κB activation 
downstream of the BCR. It induces IRF4, master regulator of terminal B cell differentiation which in turn 
activates the plasma cell master regulator BLIMP1, encoded by PRDM1 (58). GECPAR itself directly 
represses PRDM1, impeding terminal differentiation into plasma blast. In conclusion, GECPAR, which is 
induced by BCR activation, would retain B cells in the GC light zone, reducing the tendency to re-enter in the 
dark zone or to exit and differentiate to plasma cells.  
GECPAR also reduces B cell proliferation rate and the tendency to differentiate, possibly by directly inducing 
TLE4, a negative repressor of TCF/LEF1. LEF1 is the key mediator of nuclear Wnt signaling and is important 
in lymphopoiesis. LEF1 is overexpressed in the nucleus of approximately 40% of DLBCL (59). MYC and Wnt 
pathway are connected in a positive feedback-loop involving LEF1 (60). GECPAR, which directly inhibited 
MYC expression, indirectly enhanced its anti-proliferative activity via TLE4 that contributed to the arrest of 
terminal differentiation induced by NF-κB. Indeed, GECPAR expression was inversely correlated with many 
LEF1 targets, in both DLBCL cell lines and specimens, and some of them were related to NF-κB regulation. 
Moreover, GECPAR silencing induced upregulation of important NF-κB genes, such as CARD11, REL and 
IKBKB, supporting the link between GECPAR and Wnt/NF-κB crosstalk. Several bidirectional connections 
between Wnt and NF-κB pathways (45) have been reported in cancer and in particular, in DLBCL (61). We 
propose GECPAR as an additional layer of control of NF-κB activation in GC B cells, pausing terminal 
differentiation to plasma blasts.  
The greater sensitivity of ABC DLBCL with high GECPAR expression to pharmacological inhibition of Wnt 
further supports the relationship between GECPAR and Wnt pathway regulation and uncovers alternative 
therapeutic options for ABC DLBCL patients. 
In conclusion, our work describes a novel mechanism of regulation of GC differentiation, which might 
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Figure 1. POU2AF1 super-enhancer derived transcript in normal B cells and DLBCL cell lines. a, top. 
Schematic representation of transcripts annotated in chromosome 11q23, between POU2AF1 and BTG 
genes, according UCSC Genome Browser. Bottom, close-up of LOC100132078 annotated transcript, 
aligned with CAGE signals on strand plus and minus, transcripts sequenced and reconstructed in RNA poly 
A + or polyA- from CD20+ cells, and histone marks from ENCODE project. Red lines show positions of exact 
5' and 3' ends of GECPAR determined by RACE in OCI-LY1. Arrows indicate position of primers used for 5' 
and 3' RACE, in particular red arrows primers used for the retrotranscription step. b. 5’ (left) and 3’ (right) 
RACE performed in OCI-LY1. Numbers on the right of the bands indicate the exact nucleotides 
corresponding to 5’ and 3’ends of GECPAR respect to nucleotide +1, the TSS of annotated LOC100132078. 
c. GECPAR level measured by qRT in subcellular compartments in four DLBCL cell lines, two GCB and two 
ABC. d. GECPAR level measured by qRT in total RNA transcripts or polyadenylated only, in four DLBCL cell 
lines. Data are mean ± SD of independent determinations. * P <0.05. 
Figure 2. GECPAR specific expression in GC B cells and correlation with essential genes. a, top, 
GECPAR expression in a panel of 22 DLBCL cell lines, 16 GCB and 8 ABC, bottom, expression level of 
GECPAR antisense transcript, measured as control. b, top, Box plots of GECPAR expression quantified by 
total RNA seq in normal individuals or GCB or ABC DLBCL patients. Bottom, box plots of GECPAR 
expression in normal individuals stratified for cell of origin. c, Heat map of differential gene expression, in 
GCB DLBCL cell lines dichotomized for GECPAR expression. d, Preranked gene set enrichment analysis, in 
GCB DLBCL cell lines classified for GECPAR expression. e, Heat map of differential gene expression, in 16 
GCB-DLBCL patients, classified for GECPAR expression. f, Preranked gene set enrichment analysis, in 
DLBCL patients classified for GECPAR expression 
Fig 3. GECPAR anti proliferative activity and activation of GCB transcriptional program. a, 
Proliferation assay after interference with GECPAR by four different LNA antisense oligonucleotides in 
U2932, VAL and OCI-LY18. Average of three independent experiments * P <0.05, ** P <0.01. b, Growth 
curve of SUDHL2 GFP+ and SUDHL2 Gecpar- GFP+, left, or OCI-Ly10 GFP bright and SUDHL2 Gecpar- 
GFP bright , right, measured by Incucyte. Average of three independent experiments * P <0.05, ** P <0.01c, 
Preranked GSEA of RNAseq data after GECPAR knock down in U2932. d, Preranked GSEA of RNAseq 
data in GECPAR overexpressing SUDHL2 respect to control. e, GECPAR expression in four PDX models 
derived from two ABC and two GCB patients. f, Left, Proliferation assay in PDX-RN five days after GECPAR 
knock down. Right, Proliferation assay in PDX-KD nine days after GECPAR infection. 
Figure 4. GECPAR has a favorable impact on the outcome of GCB DLBCL patients. a, Kaplan-Meier 
curves of DLBCL patients treated with R-CHOP and stratified for GECPAR expression. b, Kaplan-Meier 
curves of GCB and ABC DLBCL patients treated with R-CHOP and stratified for GECPAR expression.   
Fig.5 GECPAR in trans transcriptional regulatory function. a. Pipeline of CHART experiment and 
analysis. b, Panther gene ontology classification of 325 GECPAR target genes identified both in OCI-LY1 
and U2932 by CHART. c, Preranked GSEA of RNAseq data after GECPAR knock down in U2932 d, 
Preranked GSEA of RNAseq data after GECPAR overexpression in SUDHL2 e, Top, Venn diagram crossing 
genes with GECPAR binding detected by CHARTseq and significant expression modulation after GECPAR 
knocked down, in U2932. Direct downregulated (left) and upregulated (right) GECPAR targets are listed. 
Bottom, preranked GSEA of direct GECPAR positively regulated targets, in GCB DLBCL patients 
dichotomized for GECPAR expression  
Fig.6 Wnt inhibitor sensitivity in ABC-DLBCL cell lines in dependence of GECPAR expression. a, 
Anticorrelation between AZ6102 Log IC50 and GECPAR expression, left, or tankirase protein level, right, in 
ABC DLBCL cell lines. b Cell cycle analysis in two different GECPAR overexpressing SUDHL2 clones and 
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SUPPLEMENTARY METHODS 
Cell lines, small interfering RNA transfection and drug treatment 
A total of 22 established human DLBCL cell lines were used: six ABC DLBCL (RIVA, HBL-1, U2932, SUDHL-
2, OCI-LY-3, OCI-LY-10) and  16 GCB DLBCL (Pfeiffer, OCI-LY-1, OCILY-2, OCI-LY-7, OCI-LY-8, OCI-LY-
18, OCI-LY-19, KARPAS422, SU-DHL-4, SU-DHL-6, SU-DHL-16, SUDHL-8, SUDHL-10, FARAGE, VAL, 
TOLEDO, DOHH2). Cell lines were grown as previously described (1, 2). Cell lines identity was validated by 
STR DNA fingerprinting using the Promega GenePrint 10 System kit (B9510) (2). PDTX-RN, PDTX-SS, PDTX-
KD and PDTX-RRR are Patient Derived Tumor Xenograft Cell lines (PDTX-CL) spontaneously derived from 
DLBCL patient derived tumor xenograft (PDTX) models (NY-PDTX-RN, NY-PDTX-SS, NY-PDTX-KD and NY-
PDTX-RRR PDTX) cultured in vitro. Established PDTX-CL were maintained in RPMI 20% FBS 1% penicillin 
and streptomycin and 0.2 % Normocin (Invivogen)The siGL3 Negative Control siRNA (3) and siRNA-461 or 
563 were purchased from Thermo Fisher, scramble control, LNA 461, LNA489, LNA 563 and LNA 856 from 
Qiagen. Sequences are reported in supplementary table S9. Cells (1 million per sample) were transfected with 
siRNAs (200 pmol) or LNA (1 nmol) using 4D Nucleofector (Amaxa-Lonza), according to the manufacturer’s 
instructions and incubated for 24h. Cells were treated with OTX-015 (birabresib) (Selleckchem, Houston, TX, 
USA), or DMSO (Sigma) for 4h. Cells were treated with AZ6102 (Selleckchem) or DMSO for 48h. 
Human subjects 
All patients providing samples gave written informed consent. Molecular and clinical data acquisition and 
analysis and PDTX establishment were approved and carried out in accordance with Declaration of Helsinki 
and were approved by Institutional Review Boards of the New York Presbyterian Hospital, Weill Cornell 
Medicine (WCM), New York, NY, and Ospedale San Giovanni Battista delle Molinette, Turin, Italy. 
IgM stimulation 
Cells (3 million) per sample were washed and the pellet resuspend in 100 ul of PBS with 20 ug of anti-IgM or 
no antibody in 1.5 ml vials. After 30 minutes, IgM was washed out and RNA extracted 2.5h or 6h later. 
Cell proliferation assay 
Cells nucleofected with siRNAs or LNA oligonucleotides, or treated with AZ6102 were cultured for 72 h at 37°C 
5% CO2. Proliferation was assessed by MTT assay, as previously described (1). Proliferation of cells stably 
expressing GECPAR or of PDTX-RN after transient GECPAR knock down was followed in real time by Incucyte 
(Sartorius) live cells analysis for at least five days. Briefly, cells were counted and seeded in triplicates in 96-
well plate coated with poly- L-ornithine (Sigma) to allow a monolayer growth. Different cell densities were 
tested to select the best cellular concentration for each model (OCI-Ly10, 10,000 cells/well, SUDHL2, 20,000 
cells/well, PDTX-RN, 30,000 cells/well) Every 4h independent images (n=9) were acquired per each well.  
Analysis was performed by Incucyte Cell-by-Cell Analysis Software Module and cell proliferation was quantified 
by counting the number of phase objects over time. Cells expressing GFP were also counted by green object 
count module, based on fluorescence intensity. The count average of nine images was calculated for each 
replicate and normalized to the first acquired count (t0). A specific green fluorescence threshold (GCU, green 
calibrated unit) was calculated for each cell line to distinguish cells with different fluorescence intensity.  
Statistical significance was determined using a two-tailed t-test with a threshold of p< 0.05. 
RNA extraction  
Total RNA was obtained from cell lines by phenol:chloroform extraction. RNA samples were treated with 
DNase I (Qiagen). To examine intracellular distribution of the transcripts cellular lysates were fractionated as 
previously described.(4)  
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
Strand-specific quantitative RT-PCR (qRT-PCR) was performed using Quanti Fast SYBR Green RT-PCR Kit 
(Qiagen) on an ABI Step One Plus (Applied Biosystems). Only the forward primer was added to the reverse 
transcriptase reaction to selectively amplify the antisense strand and only the reverse primer to selectively 
amplify the sense strand. PolyA+ RNA was reverse transcribed with Superscript III and oligo dT while total 
RNA was reverse transcribed with random hexamers; mRNAs were measured from cDNA reverse transcribed 
with the SuperScript III First-Strand Synthesis SuperMix (ThermoFisher). Quantitative real time PCR (qPCR) 
was then performed using the SYBR Green FAST qPCR mix (KAPA Biosystem). qRT-PCR data were analyzed 
using ∆Ct method after estimation of PCR efficiency with LinREG PCR software (5) and then normalized to 
GAPDH or β-actin as reference genes. Statistical significance was determined using a two-tailed t-test with a 
threshold of p< 0.05. Primer sequences are reported in Supplementary Table 10.  
5’ and 3’ Rapid Amplification of cDNA Ends 
5’ RACE was performed with gene-specific primers for GECPAR (Supplementary Table 10) using the 
Invitrogen 5’ RACE System and RNA from OCI-LY1 cells. cDNA was purified, tailed with dCTP and amplified 
consecutively with gene specific primers and either Abridged Anchor primer or Abridged Universal 
Amplification primer provided in the 5’RACE system kit. For 3’ RACE, total RNA was polyadenylated with 
Poly(A) tailing kit (Applied Biosystem), or not. Artificially or naturally polyadenylated RNA was then reverse 
transcribed and amplified consecutively with gene-specific primers using theInvitrogen 3’RACE system kit. 
Final PCR products were cloned into the pGEM-T Easy vector (Promega) and sequenced. 
GECPAR cloning and overexpression 
The GECPAR sequence of 968 bp derived from RACE analysis was amplified from genomic DNA of OCI-LY1 
cells using Expand™ High Fidelity PCR System (Roche), cloned into the pGEM T vector (Promega) and 
subcloned in pCDH-CMV-MCS-EF1-copGFP (System Biosciences, CD511B-1) using XbaI and BamHI 
restriction sites. Primers containing the restriction sites for PCR amplification are shown in Table S3. Plasmids 
were amplified in JM109 competent cells and purified by GenElute Plasmid Midiprep Kit (Sigma). DNA 
sequences of the construct was confirmed by DNA sequencing. 
pCDH empty backbone or pCDH_GECPAR were transfected in HEK293 T together with pMD2.VSVG, 
envelope plasmid, and pCMV-R8.74, packaging plasmid. After 72h viral supernatant was collected and used 
to infect SUDHL2 or OCI-Ly10 cells (6 ml of viral supernatant, containing polybrene, 8µg/ml per 1 million 
lymphoma cells). After three consecutive infections, cells were washed and allowed to recover for 6 days 
before sorting by FACS to enrich for GFP+ cells. After 48h RNA was extracted to determine  GECPAR 
overexpression Cells were then cultured and counted for 11 days to obtain proliferation curves, or seeded for 
Incucyte experiment. 
PDTX-KD (2 million) were infected with 200 µl of viral particles concentrated 100-fold by Lenticoncentrator 
(Takara) according to manufacturing instructions. Virus was incubated with the cells in 4 ml of medium 
containing polybrene 8µg/ml, for 24h. Than cells were washed and seeded 30000 in 96-well plate for 
proliferation assay, or cultured at 1 million/ml to extract RNA and check GFP expression at the end of 
proliferation assay. 
In Silico Genomic Analysis  
Public datasets of RNA-Seq from poly A+ and polyA- RNA of CD20+ cells and ChIP-Seq for H3K4 me1, H3K4 
me3 and H3K27ac performed in K562 and GM12878, available in the Genome Browser at the UCSC Genome 
Bioinformatics Site (http://genome.ucsc.edu/index.html), were downloaded and reanalyzed to quantify the 
bidirectional transcription at POU2AF1 super-enhancer locus.  
The RNA-Seq datasets were pre-processed and analyzed following the ENCODE RNA-Seq pipeline. All details 
are available at https://www.encodeproject.org/pipelines/ENCPL002LPE/.  
ChIP-Seq analysis  
Public datasets of ChIP-Seq for BRD4, H3ac, H3K27me3 and RNA pol II after DMSO or JQ1 treatment of OCI-
LY1 were downloaded and re-analyzed. Sequence reads obtained from ChIP fragments were aligned to 
human reference genome hg19 using Bowtie, allowing up to one mismatch per fragment length. Redundant 
reads were removed and only reads uniquely mapping to the reference genome were used for further analysis. 
The detection of peaks that are genomic regions enriched by ChIP, relative to the background reads, was 
carried out using HOMER (v2.6) (6), as previously described (7). All discovered putative peaks were ranked 
by their Normalized Tag Counts (number of tags found at the peak, normalized to 10 million total mapped tags) 
and annotated with annotatePeaks.pl subroutine. 
RNA-Seq analysis 
Total RNA-Seq reads from DLBCL patients (8) were kindly provided by G.I. and L.C.. The raw reads were 
quality assessed using fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). For each sample 
the distribution of unique, multi- and unmapped reads was checked for high proportions of unmapped or multi 
mapped reads. Reads obtained from RNA sequencing were mapped against the human hg38 genome build 
using the Genecode version 22 annotation. Alignment was done with STAR (v2.4.0h) (9), counting of reads 
overlapping gene features with HTSeq-Count. Differential gene expression analysis was performed using the 
voom/limma (10) R package. Transcripts that were expressed at > = 1 count per million mapped reads were 
considered for further analyses. Differentially expressed genes were defined as those with an empirical Bayes 
corrected (Benjamini- Hockberg procedure) p-value <0.05.  
PolyA RNA-Seq was performed in U2932 transfected with GECPAR LNA 461, GECPAR LNA 563 or scramble 
control for 48h and in SUDHL2 stably overexpressing GECPAR and GFP or GFP alone. RNA was extracted 
and libraries prepared using NEBNext Ultra II Directional RNA Library Prep. 
Public murine polyA RNA-Seq data (GSE72018) were interrogated to represent GECPAR expression by box 
plot graphs.  
DNA Copy Number Alteration analysis 
The cohort of patients analyzed for copy number alteration comprised 737 cases of mature lymphoid tumors 
and were previously described (11-15). 
Microarray analysis  
Gene expression profiles of untreated lymphoma cell lines were retrieved from our previously deposited NCBI 
GEO series GSE94669, and analyzed as previously described (1). Gene expression profiling of DLBCL patient 
samples was downloaded from GEO (GSE10846), the dataset includes 181 clinical samples from CHOP-
treated patients and 233 clinical samples from Rituximab-CHOP-treated patients. The data were analyzed 
with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling 
as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 500. 
Kaplan-Meier analysis 
Survival functions were defined according to the revised National Cancer Institute criteria and estimated 
using the Kaplan-Meier method. Patient groups were defined using the GECPAR gene expression profile: 
high expressor if GECPAR expression is higher than the 70th percentile and low expressor if the GECPAR 
expression is lower than the 15th percentile. The patients group were compared by the log-rank test. Cox 
proportional hazard models were used for univariate analysis and the estimation of hazard ratios (HRs). 
 
CHARTseq 
CHART Enrichment and RNAseH Mapping experiments were performed as previously described (16, 17). 
CHART extracts were prepared from 7 x 107 OCI-LY1 and U2932 per pulldown and hybridized with 750 pmol 
biotinylated oligonucleotides cocktail (IDT) (Supplementary Table S11) overnight with rotation at room 
temperature. Complexes were captured with 60 µl per sample of Streptavidin beads (Sigma), extensively 
washed and DNA eluted with RNAseH (Sigma) treatment. Cross-linking was reversed in the presence of 
Proteinase K (Roche), and DNA purified with a PCR purification kit (Qiagen). CHARTseq was performed in 
both cell lines with two independent samples of pulldown and matched negative control. An input DNA was 
also prepared and sequenced for each sample. The sequencing of the pre-pools was performed using the 
NextSeq500 sequencer with v2.0 chemistry from Illumina (San Diego, CA, USA) and 75 bp single reads. The 
NEBNext Ultra II DNA Library Prep Kit with Purification beads for Illumina (cat.n E7103S New England BioLabs 
Inc.) was employed with the NEBNext Multiplex Oligos for Illumina (cat.n. E7600S New England BioLabs Inc.) 
for libraries preparation. 75 bp single-end reads were mapped to hg19 using Bowtie aligner recording positions 
of uniquely mappable reads. The enrichment of CHART signal was determined relative to the oligo controls. 
Conservative enrichment profiles were determined using the SPP package (18) (lower bound of enrichment 
was determined based on a Poisson model, with a confidence interval of p <0.001) and MACS (19) (-B –-bw 
120 --broad), as described by Vance and colleagues. (20). 
Data mining 
For exploratory GECPAR function studies, differences in GEP of GCB DLBCL cell lines dichotomized for 
GECPAR expression based on median expression value were defined as statistically significant if log FC was 
> |0.59| with a P < 0.05 using the empirical Bayes moderated t-test as implemented in the LIMMA R-package 
by Carmaweb (https://carmaweb.genome.tugraz.at/carma) (17) Hierarchical clustering dendrograms and 
heatmaps for  GCB DLBCL patients stratified by median GECPAR expression were created using the 
“heatplot” function of the bioconductor package made4 (21). Functional annotation was performed using Gene 
Set Enrichment Analysis (GSEA) (22) with all genes preranked by FC as determined by Limma test. Gene sets 
were considered significantly enriched if p < 0.05 and FDR<0.25. Gene ontology analysis was performed using 
the g-Profiler webtool. The p-value for pathway enrichment was computed using a Fisher’s exact test and 
multiple-test correction was applied.  
Characterization of GECPAR binding sites 
Genes which were identified as GECPAR-bound from CHART analysis in OCI-LY1 and U2932, were 
functionally annotated by Panther (http://www.pantherdb.org/) (23) with Fisher's Exact with FDR multiple test 
correction. Peaks were considered concomitant in OCI-LY1 and U2932 if overlapping within a range of 10kb, 
as determined by BEDtool. Their FASTA sequences were interrogated by MEME software (24) for de novo 
motif discovery.  
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
RT-PCR was performed using Verso 1 Step kit Thermostart (ThermoScientific with the indicated primers (Table 
S10). Samples were analyzed by agarose gel electrophoresis followed by staining with GelRed (Biotium) and 
imaging with AlphaImager (Innotech). To distinguish the strand direction of transcripts only the forward primer 
was added to the reverse transcriptase reaction to selectively amplify the antisense strand and only the reverse 
primer to selectively amplify sense strand. 
Western blotting 
U2932 nucleofected with LNAs against GECPAR were lysed 72h after treatment by hot SDS lysis buffer. 
SUDHL2 and OCI-Ly10 pCDH or pCDH GECPAR were lysed when they were in exponential growth. 10 µg of 
extracted proteins were separated on 4–20% precast polyacrylamide gel (Biorad). Immunoblotting was 
performed with the following antibodies: anti-TLE4 antibody (Abcam, ab140485), anti-CYLD antibody - N-
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RAD21   
NCBP1   
NUP214   
EIF2B3   
U2AF2   
ZNF207   
CCT3   
COPS5   
DHX9   
CCT2   
SFPQ   
KIF11   
RNPS1   
HCFC1   
MED14   
POLA1   
TCERG1   
ABCE1   
DDX21   
E2F5   
SNRPB   
AP2M1   
POLR2B   
COPS6   
TPR   




Table S6. List of essential genes enriched in U2932 depleted of GECPAR (left) or in SUDHL2 1 
overexpressing GECPAR (right) 2 
  3 
10 
 
Table S9. siRNAs and LNAs 4 
NAME SENSE STRAND ANTISENSE STRAND 
GECPAR +461 siRNA ACUGAUCUAAAGCCAAAGUTT ACUUUGGCUUUAGAUCAGUTT 
GECPAR +563 siRNA GUGCUAUGAGGGAGUGAUUTT AAUCACUCCCUCAUAGCACTT 
GL3 siRNA CUUACGCUGAGUACUUCGATT UCGAAGUACUCAGCGUAAGTT 
SCR LNA ---------------------------------------- AA+CCATT+CTCC+GTCAA+ACC 
GECPAR +461 LNA ---------------------------------------- AC+TT+TGGCTT+TAGA+TCAGT 
GECPAR +563 LNA ---------------------------------------- AA+TCACT+CCCT+CATAG+CAC 
GECPAR +489 LNA ---------------------------------------- C+ATAGC+ACTG+TCTGAGGG+CT 
GECPAR +856 LNA ---------------------------------------- AGT+TCTGAC+TTGGCT+TCTG+T 





































Table S10 Primers 40 
NAME SEQUENCE APPLICATION 
GECPAR +545 Fw GTGGTCAGCCCTCAGACAGT 3’RACE, RT-PCR 
GECPAR +625 Rev CAGCATGAACTGCCCCTAAT 5’RACE, RT-PCR 
GECPAR+804 Fw ACCTAGGCGATGACCTTGTG 3’RACE, RT-PCR 
GECPAR +900 Rev GGCTGCACTTGCTTCTCTCT 5’RACE, RT-PCR 
LOC100132078+3473 Rev TTGAAAGCAGCAGCGAAAG 3’RACE 
POU2AF1 ex2 Fw AGGAGCCAGTGAAGGAACTG qRT-PCR 
POU2AF1 ex4 Rev GGCAGCCTCCTCTGTCACT qRT-PCR 
CREBBP ex9 Fw CATGTACGAGTCTGCCAACAG qRT-PCR 
CREBBP ex10 Fw GCGACCTCCGTTTTTCTTCT qRT-PCR 
CREB5 ex6 Fw AACCCTACAATGCCAGGATCT qRT-PCR 
CREB5 ex7 Rev CACAGGGGTTGCTGAGATTT qRT-PCR 
TLE4 ex12 Fw GGATTTGATCCACACCATCA qRT-PCR 
TLE4 ex13 Rev TCTGACCATCTGCGCTAACA qRT-PCR 
CYLD Fw CAGCCGGTTTCCAATCAG qRT-PCR 
CYLD Rev ACCCTGGATGCCTTTCTTCT qRT-PCR 
GAPDH ex3 Fw TCACCAGGGCTGCTTTTAAC qRT-PCR 
GAPDH ex4 Rev GGGTGGAATCATATTGGAACA qRT-PCR 
GAPDH ctr neg Fw  CGTAGCTCAGGCCTCAAGAC qPCR 
GAPDH ctr neg Rev GTCGAACAGGAGGAGCAGAG qPCR 
ALBUMIN ctr neg Fw  TTGCTAGATGGAGGGCAAAC qPCR 
ALBUMIN ctr neg Rev TTTAAATCCGCACCCTTCTG qPCR 
BACH2_GECPAR_BS Fw ATGTGGGGTCCTTTCCTTCT qPCR 
BACH2_GECPAR_BS Rev TTGGAACCCAGTGAAAGATG qPCR 
11q23_GECPAR_BS Fw AGCCACTCCTCGCAGTCTT qPCR 
11q23_GECPAR_BS Rev GAGTCAGAATGTTGAAAGGCATAA qPCR 
TTK_GECPAR_BS FW AATGGGACCATTTAAGTGAAAG qPCR 
TTK _GECPAR_BS REV TCCTGAAGGAAATATCACAGAGTG qPCR 
ACTL6A_ GECPAR _BS FW GACCCAGAAAACAAATCCAGAC qPCR 
ACTL6A_ GECPAR _BS REV GGGGAACATGAAGGAAAAATC qPCR 
ATP11B_ GECPAR _BS FW ACAGCTGATGCCTGGAGTTC qPCR 
ATP11B_ GECPAR _BS REV GCATTAGCTGAGGTGGATTG qPCR 
XRCC4_ GECPAR _BS FW ACAGATGTCTCTTCCACATTCTGA qPCR 
XRCC4_ GECPAR _BS REV ATCCAGCAATCCCACTTCTG qPCR 
MCTP_ GECPAR _BS FW TGGTAGTCATCCTCTGTCCAAATA qPCR 
MCTP_ GECPAR _BS REV CAAATGCGTTCCTATGTGTCA qPCR 
BET1_ GECPAR _BS FW AAGGGGTTGGCTATCTCTGA qPCR 
BET1_ GECPAR _BS REV ATTGTCATGCATGGCTTCTG qPCR 
CREB5_ GECPAR _BS FW TTAACCAAGGTTCCCCACAG qPCR 
CREB5_ GECPAR _BS REV AGAGGTGGACAACCCAACTG qPCR 
ECT2_ GECPAR _BS FW GGAATCTACACAGCCGTTACAA qPCR 
ECT2_ GECPAR _BS REV GGTAATGAACATCTTTCCAGGTCTA qPCR 
XbaI GECPAR Fw  GCTCTAGAGCGCAGTGATTCAAGACACTTGG GECPAR cloning 













Table S11 CHART probes 51 
NAME SEQUENCE APPLICATION 
GECPAR_AS_oligo_1 CCTGGTTTCCAGTTTAGTTGTTC RNAseH mapping 
GECPAR _AS_oligo_2 TCCCTGGTTTCCAGTTTAGTTGT RNAseH mapping 
GECPAR _AS_oligo_3 GTTCCTGTTGTTATGCCTGAGGA RNAseH mapping 
GECPAR _AS_oligo_4 GTGTTCCTGTTGTTATGCCTGAG RNAseH mapping 
GECPAR _AS_oligo_5 CTGTGTTCCTGTTGTTATGCCTG RNAseH mapping 
GECPAR _AS_oligo_6 GCTTTGTGGAGAGTAAGACGTCG RNAseH mapping 
GECPAR _AS_oligo_7 TTGACCAAACTTGGCTTTGTGGA RNAseH mapping 
GECPAR _AS_oligo_8 GGAGCTTGACCAAACTTGGCTTT RNAseH mapping 
GECPAR _AS_oligo_9 CTTAGGGGATTTCCTCTCTGTGG RNAseH mapping 
GECPAR _AS_oligo_10 AACTTAGGGGATTTCCTCTCTGT RNAseH mapping 
GECPAR _AS_oligo_11 GTTTTCATGTTCTTGGGGCATGG RNAseH mapping 
GECPAR _AS_oligo_12 GGACTGTTTTCATGTTCTTGGGG RNAseH mapping 
GECPAR _AS_oligo_13 GCATCTGGACTGTTTTCATGTTC RNAseH mapping 
GECPAR _AS_oligo_14 TGCATTGCAGGTTCATGCATCTG RNAseH mapping 
GECPAR _AS_oligo_15 TAGCACTGTCTGAGGGCTGACCA RNAseH mapping 
GECPAR _AS_oligo_16 TCCCTCATAGCACTGTCTGAGGG RNAseH mapping 
GECPAR _AS_oligo_17 CAATCACTCCCTCATAGCACTGT RNAseH mapping 
Biotin_AS_oligo_2  TCCCTGGTTTCCAGTTTAGTTGT CHART 
Biotin _AS_oligo_4 GTGTTCCTGTTGTTATGCCTGAG CHART 
Biotin _AS_oligo_6 GCTTTGTGGAGAGTAAGACGTCG CHART 
Biotin _AS_oligo_16 TCCCTCATAGCACTGTCTGAGGG CHART 
Biotin_scr-oligo1 ctCCactgatCAtgcTgtcgGaG CHART 



























Table Captions 76 
Table S1 (separate file) 77 
Limma results comparing gene expression profiles of GCB-DLBCL cell lines dichotomized by median GECPAR 78 
expression. MeanM represents modulation (fold change) for each gene in high GECPAR vs low GECPAR 79 
expression level. 80 
Table S2 (separate file) 81 
Limma test performed on gene expression profiles of GCB-DLBCL patients dichotomized for median GECPAR 82 
expression. LogFC represents modulation for each gene in high GECPAR vs low GECPAR expression level. 83 
Table S4 (separate file) 84 
Limma test performed on gene expression profile of U2932 after GECPAR knockdown versus control. LogFC 85 
represents modulation for each gene in GECPAR knockdown vs control. 86 
Table S5 (separate file) 87 
Limma test performed on gene expression profile of SUDHL2 overexpressing GECPAR versus control. LogFC 88 
represents modulation for each gene in GECPAR overexpressing cells vs control. 89 
Table S7 (separate file) 90 
GECPAR binding sites detected by CHARTseq in OCI-LY1. Fold change represents enrichment of GECPAR 91 
binding relative to negative control. 92 
Table S8 (separate file) 93 
GECPAR binding sites detected by CHARTseq in U2932. Fold change represents enrichment of GECPAR 94 
binding relative to negative control. 95 
  96 
14 
 
Supplementary figures legends 97 
 98 
 99 
Fig. S1 a, Quantification of De Novo reconstructed transcripts in CD20+ RNAseq in correspondence of 100 
LOC100132078 transcript b. Directional semiquantitative RT-PCR of two independent experiments of 101 
subcellular fractionation of GECPAR and its antisense transcript. c, qRT-PCR of KCNQ1OT1 as a positive 102 
control for chromatin associated RNA, MALAT1 as a nuclear soluble RNA and mature beta-actin mRNA as a 103 



















Fig. S2 a,  Box plots of GECPAR expression quantified by total RNA seq in GCB or ABC DLBCL patients in a 119 
validation cohort (left),  box plots of GECPAR (middle) and POU2AF1 (right) expression quantified by 120 
microarray in a large validation cohort of GCB or ABC DLBCL patients. b, Copy number alterations of 11q23 121 
in 737 mature lymphoid tumors. The red interval indicates the genomic locus of GECPAR and its RefSeq ID 122 
and relative coordinates are indicated in the yellow box.c, Boxplots of murine GECPAR orthologue expression 123 
stratified for cell of origin, * p<0.05, **<0.005 d, Gene ontology classification by gProfiler of the essential genes 124 
commonly enriched in patients and cell lines with high GECPAR expression. e, Gene ontology classification 125 
by gProfiler of cell cycle gene set elements enriched in cell lines and patients with high GECPAR expression.  126 









Fig. S3 a,GECPAR expression 24h after interference with two different siRNA in U2932 and OCI-Ly1 and  with 132 
four different LNA antisense oligonucleotides in U2932, OCI-Ly1, VAL and OCI-Ly18. GECPAR expression is 133 
normalized to samples transfected with negative controls.  Numerical codes associated to siRNA and LNAs 134 
are referred to the first nucleotide recognized in GECPAR transcript relative to its transcription start site b, 135 
POU2AF1 gene expression after interference with GECPAR by four different LNA antisense oligonucleotides 136 
in U2932, OCI-LY1, VAL and OCI-Ly18. c, Occupancy of BRD4, H3Ac and RNA pol II at POU2AF1 and 137 
LOC100132078 loci determined by ChIP-Seq after treatment of OCI-LY1 with DMSO or JQ1. d, top, GECPAR 138 
expression in six DLBCL cell lines treated with DMSO or OTX-015 for 4 h. Pool of two independent 139 
experiments; bottom, GECPAR antisense transcript expression in 6 DLBCL cell lines treated with DMSO or 140 
OTX-015 for 4 h. Pool of two independent experiments. e, POU2AF1 downregulation 4h after OTX-015 141 
treatment in 4 DLBCL cell lines . f, MTT proliferation assay 72 h after transfection with negative controls or 142 
19 
 
siRNAs 461 or 563. Representative experiment. g, MTT proliferation assay 72 h after transfection with negative 143 
controls or LNA 461 or 563 in OCI-Ly1. Average of three independent experiments. h, GECPAR levels in 144 
SUDHL2 and OCI-Ly10 transduced with empty vector or overexpression vector. Representative experiment. 145 
i, GFP expression measured by FACS at t0 of Incucyte experiment in OCI-Ly10 and SUDHL2 stably transduced 146 
with pCDH empty vector or pCDH-Gecpar vector. H2, percentage of total GFP positive cells, H3, percentage 147 
of GFP bright cells. j, Growth curve of SUDHL2 parental and SUDHL2_overexpressing GECPAR, performed 148 
after sorting of GFP positive cells. Average of three independent experiments k, Number of total cells, GFP 149 
positive cells and GFP bright cells counted by Incucyte instrument at t0 of proliferation assay in OCI-Ly10 and 150 
SUDHL2 stably transduced with pCDH empty vector or pCDH-Gecpar vector.  l, GECPAR levels in U2932 151 
stimulated for 2.5 or 6h with 20 µg of anti-IgM. Average of three independent experiments.  152 
 153 
 154 
Fig. S4 a, GECPAR expression 48h after interference with four different LNA antisense oligonucleotides in 155 
PDTX-RN. b, Proliferation assay performed with Incucyte instrument in PDTX-RN nucleofected with negative 156 
control (SCR) and three different GECPAR specific LNA antisense oligonucleotides and followed for 8 days. 157 
Representative experiment. c, Number of total cells counted by Incucyte instruments at t0 in PDTX-KD 158 
transduced with pCDH or pCDH-Gecpar vector. d, Percentage of GFP positive PDTX-KD, 9 days after 159 
transduction with pCDH or pCDH- Gecpar vectors. e, Gecpar expression quantified by qRT-PCR in PDTX-KD, 160 










Fig. S5 a, GECPAR level in OCI-LY1 RNA extracted from chromatin after incubation with 17 different antisense 169 
oligonucleotides designed to bind GECPAR and treatment with RNAse H. b, DNA enrichment after GECPAR 170 
pulldown in U2932 (left) or OCI-LY1 (right), concordant with representative peaks from CHARTseq. c. 171 
Downregulation of direct targets of GECPAR after GECPAR inhibition by two different LNA oligonucleotides in 172 
U2932. Average of three independent experiments. * P <0.05 d. Top,  Downregulation at protein level of direct 173 
GECPAR targets after GECPAR inhibition by four different LNA oligonucleotides in U2932. Bottom, 174 
Upregulation at protein level of direct GECPAR targets of in SUDHL2 and OCI-Ly10 stably overexpressing 175 







Fig. S6 Gene ontology classification by gProfiler of TGF-β (a) and ATF2 (b) pathway gene set elements and 181 





Fig. S7. GECPAR expression and Log IC50 of AZ6102 in 7 GCB-DLBCL cell lines tested for tankyrase 185 
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